Grant of Options and Directors Dealings

13 June 2014

Akers Biosciences, Inc.

(the "Company")

Grant of Options and Directors Dealings

Akers Biosciences, Inc. (Nasdaq:AKER) (LSE:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces that on 10 June 2014 the Company approved the grant of share options over ordinary shares of no par value each in the Company to certain Directors and a senior employee under the Company's existing share option plan.

The exercise price of the options is $5.50 per ordinary share and the options are exercisable immediately. The options will lapse on the fifth anniversary of the grant.

There are no performance conditions attaching to the exercise of the options.

One other member of the Company's senior management team has received a total of 15,000 share options on identical terms to those set out above.

ABOUT AKERS BIOSCIENCES, INC.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com.

Follow us on Twitter: @AkersBio

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

For more information:

Raymond F. Akers, Jr. PhD

Executive Chairman of the Board

Akers Biosciences, Inc.

Tel. +1 856 848 8698

Twitter. @AkersBio

Brendan Hopkins

RedChip Companies, Inc. (US Investor Relations)

Tel. +1 407 644 4256 x134

Emma Earl / Harrison Clarke

Daniel Stewart (Nomad and Broker)

Tel. +44 (0)20 7776 6550

Ben Simons / Alexandra Roper

Vigo Communications (UK Investor Relations)

Tel. +44 (0)20 7016 9570

[email protected]